CYDY - What's Behind This Wild-Card Coronavirus Stock?
The U.S. Food and Drug Administration (FDA) has historically refrained from providing confidential information regarding unapproved products to protect the trade secrets of drug developers. However, the agency made a stunning exception last month with the issuance of a statement regarding CytoDyn 's (OTC: CYDY) leronlimab, which is currently being evaluated as a treatment of COVID-19.
This is the company's leading drug candidate, and is also in clinical trials to treat cancer and HIV. Just what exactly is behind the monoclonal antibody that set off the FDA?
Image source: Getty Images.
For further details see:
What's Behind This Wild-Card Coronavirus Stock?